russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLC10.15829/1560-4071-2021-4530russjcardiol-4530Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWБиомаркеры ST2 и интерлейкин 33 в оценке кардиального воспаления, фиброза и прогноза пациентов с хронической сердечной недостаточностьюBiomarkers ST2 and interleukin 33 for assessing the severity of cardiac inflammation and fibrosis in patients with chronic heart failurehttps://orcid.org/0000-0002-4453-8430ДрапкинаО. М.DrapkinaO. M.

Драпкина Оксана Драпкина — доктор медицинских наук, профессор, член-корреспондент РАН, директор

Москва

Moscow

ODrapkina@gnicpm.ruhttps://orcid.org/0000-0003-2062-1536КонцеваяА. В.KontsevayaA. V.

Концевая Анна Васильевна — доктор медицинских наук, зам. директора по научной и аналитической работе

Москва

Moscow

Akontsevaya@gnicpm.ruhttps://orcid.org/0000-0003-0297-1735КравченкоА. Я.KravchenkoA. Ya.

Кравченко Андрей Яковлевич — доктор медицинских наук, профессор, профессор кафедры факультетской терапии

Воронеж

Voronezh

drkay@yandex.ruhttps://orcid.org/0000-0002-1171-2746БудневскийА. В.BudnevskiyA. V.

Будневский Андрей Валериевич — доктор медицинских наук, профессор, заведующий кафедрой факультетской терапии

Воронеж

Voronezh

budnev@list.ruhttps://orcid.org/0000-0001-6379-4635ТокмачевР. Е.TokmachevR. E.

Токмачев Роман Евгеньевич — кандидат медицинских наук, доцент кафедры факультетской терапии

Воронеж

Voronezh

r-tokmachev@mail.ruhttps://orcid.org/0000-0003-1371-0848ЧерникТ. А.ChernikT. A.

Черник Татьяна Александровна — аспирант кафедры факультетской терапии

Воронеж

Voronezh

ch01@mail.ruНациональный медицинский исследовательский центр терапии и профилактической медициныNational Research Center for Therapy and Preventive MedicineФГБОУ ВО Воронежский государственный медицинский университет им. Н.Н. Бурденко Минздрава РоссииN.N. Burdenko Voronezh State Medical UniversityВоронежский государственный медицинский университет имени Н.Н. БурденкоРоссияN.N. Burdenko Voronezh State Medical UniversityRussian Federation202125092021263SОбразование45304530Copyright © Драпкина О.М., Концевая А.В., Кравченко А.Я., Будневский А.В., Токмачев Р.Е., Черник Т.А., 20212021Драпкина О.М., Концевая А.В., Кравченко А.Я., Будневский А.В., Токмачев Р.Е., Черник Т.А.Drapkina O.M., Kontsevaya A.V., Kravchenko A.Y., Budnevskiy A.V., Tokmachev R.E., Chernik T.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/4530

Хроническая сердечная недостаточность (ХСН) — это патология, которая охватывает >37 млн человек в мире. Несмотря на внедрение в практику новых лекарственных препаратов, доказавших свою эффективность в лечении пациентов с ХСН, продолжительность жизни этих больных растёт медленными темпами. При этом недостаточный эффект нейрогормональных блокаторов для лечения пациентов с ХСН с сохранённой фракцией выброса (ХСНсФВ), которая преобладает в общей структуре ХСН, указывает на существенную роль неустановленных патологических процессов в развитии данной формы заболевания. В рамках изучения патогенеза ХСНсФВ в последние годы активно изучается роль кардиального фиброза, вероятными биомаркерами которого являются интерлейкин (ИЛ) 33 и стимулирующий фактора роста, экспрессируемый геном 2 (ST2). В данном литературном обзоре рассматриваются влияние взаимодействия ИЛ-33/ST2 как биомаркера кардиального фиброза на течение ХСН и возможности его практического применения.

Chronic heart failure (CHF) is a pathology that affects more than 37 million people worldwide. Despite the introduction of new drugs into practice, that have proven their effectiveness in the treatment of patients with CHF, the life expectancy of these patients is growing at a slow pace. At the same time, the insufficient effect of neurohormonal blockers for the treatment of patients with CHF with preserved ejection fraction (CHFpEF), which prevails in the general structure of CHF, indicates a significant role of unidentified pathological processes in the development of this form of the disease. In recent years, the role of cardiac fibrosis has been actively studied within the framework of the investigation of the pathogenesis of CHFpEF, the probable biomarkers of which are interleukin (IL) 33 and suppression of tumorigenicity 2 (ST2). This literature review examines the influence of the IL-33/ ST2 interaction as a biomarker of cardiac fibrosis on the course of CHF and the possibilities of its practical application.

сердечная недостаточностьбиомаркерыST2ИЛ-33heart failurebiomarkersST2IL-33ReferencesZiaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016;13(6):368-78. doi:10.1038/nrcardio.2016.25.Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016;13(6):368-78. doi:10.1038/nrcardio.2016.25.Российское кардиологическое общество. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4083. doi:10.15829/29/1560-4071-2020-4083.Russian Society of Cardiology (RSC). 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):4083. (In Russ.). doi:10.15829/29/1560-4071-2020-4083.Abouezzeddine OF, Redfield MM. Who Has Advanced Heart Failure? Definition and Epidemiology. Congest Heart Fail. 2011;17(4):160-8. doi:10.1111/j.1751-7133.2011.00246.x.Abouezzeddine OF, Redfield MM. Who Has Advanced Heart Failure? Definition and Epidemiology. Congest Heart Fail. 2011;17(4):160-8. doi:10.1111/j.1751-7133.2011.00246.x.Taylor С, Ordóñez-Mena JM, Roalfe AK, et al. Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: population based cohort study. BMJ. 2019;364:l223. doi:10.1136/bmj.l223.Taylor С, Ordóñez-Mena JM, Roalfe AK, et al. Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: population based cohort study. BMJ. 2019;364:l223. doi:10.1136/bmj.l223.Go AS, Mozaffarian D, Roger VL, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation. 2014;129:399-410. doi:10.1161/01.cir.0000442015.53336.12.Go AS, Mozaffarian D, Roger VL, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation. 2014;129:399-410. doi:10.1161/01.cir.0000442015.53336.12.Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev. 2017;3(1):7-11. doi:10.15420/cfr.2016:25:2.Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev. 2017;3(1):7-11. doi:10.15420/cfr.2016:25:2.Токмачев Р.Е., Будневский А.В., Кравченко А.Я. Роль воспаления в патогенезе хронической сердечной недостаточности. Терапевтический Архив. 2016;88(9):106-10. doi:10.17116/terarkh2016889106-110.Tokmachev RE, Budnevsky AV, Kravchenko AY. The role of inflammation in the pathogenesis of chronic heart failure. Terapevticheskii Arkhiv. 2016;88(9):106-10. (In Russ.) doi:10.17116/terarkh2016889106-110.Mann DL. Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res. 2015;116:1254-68. doi:10.1161/CIRCRESAHA.116.302317.Mann DL. Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res. 2015;116:1254-68. doi:10.1161/CIRCRESAHA.116.302317.Провоторов В. М., Будневский А.В., Семенкова Г.Г., Шишкина С.В. Провоспалительные цитокины при сочетании с ишемической болезни сердца и хронической обструктивной болезни легких. Клиническая Медицина. 2015;93(2):5-9.Provotorov VM, Budnevsky AV, Semenkova GG, Shishkina SV. Proinflammatory cytokines in combination of coronary heart disease and chronic obstructive pulmonary disease. Klinicheskaia Meditsina. 2015;93(2):5-9. (In Russ.)Creemers EE, Pinto YM. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc Res. 2011;89:265-72.Creemers EE, Pinto YM. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc Res. 2011;89:265-72.Onda H, Kasuya H, Takakura K, et al. Identification of genes differentially expressed in canine vasospastic cerebral arteries after subarachnoid hemorrhage. J Cerebr Blood Flow Met. 1999;19:1279-88. doi:10.1097/00004647-199911000-00013.Onda H, Kasuya H, Takakura K, et al. Identification of genes differentially expressed in canine vasospastic cerebral arteries after subarachnoid hemorrhage. J Cerebr Blood Flow Met. 1999;19:1279-88. doi:10.1097/00004647-199911000-00013.Baekkevold ES, Roussigne M, Yamanaka T, et al. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol. 2003;163:69-79. doi:10.1016/S0002-9440(10)63631-0.Baekkevold ES, Roussigne M, Yamanaka T, et al. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol. 2003;163:69-79. doi:10.1016/S0002-9440(10)63631-0.Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23:479-90. doi:10.1016/j.immuni.2005.09.015.Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23:479-90. doi:10.1016/j.immuni.2005.09.015.Li D, Guabiraba R, Besnard AG, et al. IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice. J Allergy ClinImmunol. 2014;134:1422.e11-32. doi:10.1016/j.jaci.2014.05.011.Li D, Guabiraba R, Besnard AG, et al. IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice. J Allergy ClinImmunol. 2014;134:1422.e11-32. doi:10.1016/j.jaci.2014.05.011.Lefrancais E, Roga S, Gautier V, et al. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc Natl AcadSci USA. 2012;109:1673-8. doi:10.1073/pnas.1115884109.Lefrancais E, Roga S, Gautier V, et al. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc Natl AcadSci USA. 2012;109:1673-8. doi:10.1073/pnas.1115884109.Tominaga S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett. 1989;258:301-4.Tominaga S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett. 1989;258:301-4.Carrasco GT, Morales RA, Pérez F, et al. Alarmin’ immunologists: IL-33 as a putative target for modulating T cell-dependent responses. Front Immunol. 2015;6:232. doi:10.3389/fimmu.2015.00232.Carrasco GT, Morales RA, Pérez F, et al. Alarmin’ immunologists: IL-33 as a putative target for modulating T cell-dependent responses. Front Immunol. 2015;6:232. doi:10.3389/fimmu.2015.00232.Griesenauer B, Paczesny S. The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases. Front Immunol. 2017;8:475. doi:10.3389/fimmu.2017.00475.Griesenauer B, Paczesny S. The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases. Front Immunol. 2017;8:475. doi:10.3389/fimmu.2017.00475.Sanada S, Hakuno D, Higgins LJ, et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007;117(6):1538-49. doi:10.1172/JCI30634.Sanada S, Hakuno D, Higgins LJ, et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007;117(6):1538-49. doi:10.1172/JCI30634.Tajima S, Oshikawa K, Tominaga S, et al. The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis. Chest. 2003;124(4):1206-14. doi:10.1378/chest.124.4.1206.Tajima S, Oshikawa K, Tominaga S, et al. The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis. Chest. 2003;124(4):1206-14. doi:10.1378/chest.124.4.1206.Andersson C, Preis SR, Beiser A, et al. Associations of circulating growth differentiation factor-15 and ST2 concentrations with subclinical vascular brain injury and incident stroke. Stroke. 2015;46(9):2568-75. doi:10.1161/STROKEAHA.115.009026.Andersson C, Preis SR, Beiser A, et al. Associations of circulating growth differentiation factor-15 and ST2 concentrations with subclinical vascular brain injury and incident stroke. Stroke. 2015;46(9):2568-75. doi:10.1161/STROKEAHA.115.009026.Скворцов А.А., Протасов В.Н., Нарусов О.Ю. и др. Определение концентрации растворимого рецептора подавления туморогенности 2-го типа расширяет возможности в стратификации риска больных после перенесенной декомпенсации хронической сердечной недостаточности. Кардиология. 2017;57(1):48-58. doi:10.18565/cardio.2017.1.48-58.Skvortsov AA, Protasov VN, Narusov OYu, et al. Soluble supression of tumorogenicity 2 increases opportunities in patients long-term risk stratification after acute heart failure decompensation. Kardiologiia. 2017;57(1):48-58. (In Russ.) doi:10.18565/cardio.2017.1.48-58.Aleksova A, Paldino A, Beltrami AP, et al. Cardiac Biomarkers in the Emergency Department: The Role of Soluble ST2 (sST2) in Acute Heart Failure and Acute Coronary Syndrome — There is Meat on the Bone. Journal of Clinical Medicine. 2019;8(2):270. doi:10.3390/jcm8020270.Aleksova A, Paldino A, Beltrami AP, et al. Cardiac Biomarkers in the Emergency Department: The Role of Soluble ST2 (sST2) in Acute Heart Failure and Acute Coronary Syndrome — There is Meat on the Bone. Journal of Clinical Medicine. 2019;8(2):270. doi:10.3390/jcm8020270.McCarthy CP, Januzzi JJr. Soluble ST2 in heart failure. Heart Fail Clin. 2018;14:41-8. doi:10.1016/j.hfc.2017.08.005.McCarthy CP, Januzzi JJr. Soluble ST2 in heart failure. Heart Fail Clin. 2018;14:41-8. doi:10.1016/j.hfc.2017.08.005.Ueha S, Shand FHW, Matsushima K. Cellular and molecular mechanisms of chronic inflammation-associated organ fibrosis. Front Immunol. 2012;3:71. doi:10.3389/fimmu.2012.00071.Ueha S, Shand FHW, Matsushima K. Cellular and molecular mechanisms of chronic inflammation-associated organ fibrosis. Front Immunol. 2012;3:71. doi:10.3389/fimmu.2012.00071.Seki K, Sanada S, Kudinova AY, et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail. 2009;2:684-91. doi:10.1161/CIRCHEARTFAILURE.109.873240.Seki K, Sanada S, Kudinova AY, et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail. 2009;2:684-91. doi:10.1161/CIRCHEARTFAILURE.109.873240.Zhu J, Carver W. Effects of interleukin-33 on cardiac fibroblast gene expression and activity. Cytokine. 2012;58:368-79. doi:10.1016/j.cyto.2012.02.008.Zhu J, Carver W. Effects of interleukin-33 on cardiac fibroblast gene expression and activity. Cytokine. 2012;58:368-79. doi:10.1016/j.cyto.2012.02.008.Гракова Е.В., Копьева К.В., Тепляков А.Т. и др. Возможности клинического применения нового биомаркера ST2 у больных с хронической сердечной недостаточностью ишемического генеза: тест с физической нагрузкой. Кардиоваскулярная терапия и профилактика. 2019;18(4):12-8. doi:10.15829/1728-8800-2019-4-12-18.Grakova EV, Kopieva KV, Teplyakov АT, et al. Clinical use of the new biomarker ST2 in patients with chronic heart failure of ischemic genesis: an exercise test. Cardiovascular Therapy and Prevention. 2019;18(4):12-8. (In Russ.) doi:10.15829/1728-8800-2019-4-12-18.Ky B, French B, McCloskey K, et al. High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure. Circulation: Heart Failure. 2011;4:180-7. doi:10.1161/CIRCHEARTFAILURE.110.958223.Ky B, French B, McCloskey K, et al. High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure. Circulation: Heart Failure. 2011;4:180-7. doi:10.1161/CIRCHEARTFAILURE.110.958223.Huang WP, Zheng X, He L, et al. Role of Soluble ST2 Levels and Beta-Blockers Dosage on Cardiovascular Events of Patients with Unselected ST-Segment Elevation Myocardial Infarction. Chin Med J (engl). 2018;131(11):1282-8. doi:10.4103/0366-6999.232819.Huang WP, Zheng X, He L, et al. Role of Soluble ST2 Levels and Beta-Blockers Dosage on Cardiovascular Events of Patients with Unselected ST-Segment Elevation Myocardial Infarction. Chin Med J (engl). 2018;131(11):1282-8. doi:10.4103/0366-6999.232819.Gaggin HK, Motiwala S, Bhardwaj A, et al. Soluble Concentrations of the Interleukin Receptor Family Member ST2 and β-Blocker Therapy in Chronic Heart Failure. Circulation: Heart Failure. 2013;6:1206-13. doi:10.1161/CIRCHEARTFAILURE.113.000457.Gaggin HK, Motiwala S, Bhardwaj A, et al. Soluble Concentrations of the Interleukin Receptor Family Member ST2 and β-Blocker Therapy in Chronic Heart Failure. Circulation: Heart Failure. 2013;6:1206-13. doi:10.1161/CIRCHEARTFAILURE.113.000457.Weir RA, Miller AM, Murphy GE, et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol. 2010;55:243-50.Weir RA, Miller AM, Murphy GE, et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol. 2010;55:243-50.Anand IS, Rector TS, Kuskowski M, et al. Prognostic Value of Soluble ST2 in the Valsartan Heart Failure Trial. Circulation: Heart Failure. 2014;7:418-26. doi:10.1161/CIRCHEARTFAILURE.113.001036.Anand IS, Rector TS, Kuskowski M, et al. Prognostic Value of Soluble ST2 in the Valsartan Heart Failure Trial. Circulation: Heart Failure. 2014;7:418-26. doi:10.1161/CIRCHEARTFAILURE.113.001036.Bayes-Genis A, de Antonio M, Galán A, et al. Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. Eur J Heart Fail. 2012;14:32-8.Bayes-Genis A, de Antonio M, Galán A, et al. Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. Eur J Heart Fail. 2012;14:32-8.Nah EH, Cho S, Kim S, et al. Reference interval and the role of soluble suppression of tumorigenicity 2 (sST2) in subclinical cardiac dysfunction at health checkups. J Clin Lab Anal. 2020;34(11):e23461. doi:10.1002/jcla.23461.Nah EH, Cho S, Kim S, et al. Reference interval and the role of soluble suppression of tumorigenicity 2 (sST2) in subclinical cardiac dysfunction at health checkups. J Clin Lab Anal. 2020;34(11):e23461. doi:10.1002/jcla.23461.Firouzabadi N, Dashti M, Dehshahri A, et al. Biomarkers of IL-33 and sST2 and Lack of Association with Carvedilol Therapy in Heart Failure. Clin Pharmacol. 2020;12:53-8. doi:10.2147/CPAA.S256290.Firouzabadi N, Dashti M, Dehshahri A, et al. Biomarkers of IL-33 and sST2 and Lack of Association with Carvedilol Therapy in Heart Failure. Clin Pharmacol. 2020;12:53-8. doi:10.2147/CPAA.S256290.Tseng CCS, Huibers MM, Gaykema L, et al. Soluble ST2 levels in end-stage heart failure and during LVAD support. The Journal of Heart and Lung Transplantation. 2016;35(4S Abstract Supplement Issue):S12. doi:1016/j.healun.2016.01.035.Tseng CCS, Huibers MM, Gaykema L, et al. Soluble ST2 levels in end-stage heart failure and during LVAD support. The Journal of Heart and Lung Transplantation. 2016;35(4S Abstract Supplement Issue):S12. doi:1016/j.healun.2016.01.035.Tseng CCS, Huibers MM, Kuik J, et al. The Interleukin-33/ST2 Pathway Is Expressed in the Failing Human Heart and Associated with Pro-fibrotic Remodeling of the Myocardium. J Cardiovasc Transl Res. 2018;11(1):15-21. doi:10.1007/s12265-017-9775-8.Tseng CCS, Huibers MM, Kuik J, et al. The Interleukin-33/ST2 Pathway Is Expressed in the Failing Human Heart and Associated with Pro-fibrotic Remodeling of the Myocardium. J Cardiovasc Transl Res. 2018;11(1):15-21. doi:10.1007/s12265-017-9775-8.Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37(27):2129-200. doi:10.1093/eurheartj/ehw128.Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37(27):2129-200. doi:10.1093/eurheartj/ehw128.Sabatine MS, Morrow DA, Higgins LJ, et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation. 2008;117:1936-44.Sabatine MS, Morrow DA, Higgins LJ, et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation. 2008;117:1936-44.Rehman SU, Mueller T, Januzzi JL. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am CollCardiol. 2008;52:1458-65.Rehman SU, Mueller T, Januzzi JL. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am CollCardiol. 2008;52:1458-65.Pascual-Figal DA, Ordoñez-Llanos J, Tornel PL. Soluble ST2 for Predicting Sudden Cardiac Death in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction. 2009;54(23):2174-9. doi:10.1016/j.jacc.2009.07.041.Pascual-Figal DA, Ordoñez-Llanos J, Tornel PL. Soluble ST2 for Predicting Sudden Cardiac Death in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction. 2009;54(23):2174-9. doi:10.1016/j.jacc.2009.07.041.

The authors declare that there are no conflicts of interest present.